Singapore markets open in 6 hours 59 minutes
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,466.70 -2.60 (-0.05%) Dow
39,150.80 +38.64 (+0.10%) Nasdaq
17,755.78 +38.12 (+0.22%) Bitcoin USD
61,182.88 -254.07 (-0.41%) CMC Crypto 200
1,265.29 -18.49 (-1.44%)
Bristol-Myers Squibb Co (BRM.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 07:15PM CEST. Market open.
| Previous close | 39.14 |
| Open | 39.29 |
| Bid | 39.71 x 500000 |
| Ask | 39.85 x 100000 |
| Day's range | 39.28 - 39.94 |
| 52-week range | 37.00 - 59.50 |
| Volume | |
| Avg. volume | 834 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J., June 21, 2024--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with...
- Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
PRINCETON, N.J., June 21, 2024--European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
- Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
PRINCETON, N.J., June 20, 2024--Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
© 2024 Yahoo. All rights reserved.